We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Identified Protein Biomarkers in Blood Predict Sudden Cardiac Arrest Before it Strikes

By LabMedica International staff writers
Posted on 27 Jan 2023

Sudden cardiac arrest, or the sudden loss of heartbeat, is a life-threatening heart condition and often fatal. More...

Despite providing an organized emergency medical response, less than 10% of individuals having a cardiac arrest will survive. Hence, there is a need for risk determination, early prediction, and improved primary prevention of sudden cardiac arrest. Now, researchers have identified a panel of novel blood biomarkers specifically associated with sudden cardiac arrest. These biomarkers have the potential to enhance the clinical prediction of sudden cardiac arrest.

In a collaborative study, investigators at Cedars-Sinai (Los Angeles, CA, USA) analyzed a number of blood biomarkers obtained from survivors of sudden cardiac arrest. They compared the results from one cohort of people without coronary artery disease and one cohort with the disease. The researchers identified 26 protein biomarkers associated with sudden cardiac arrest that could improve the prediction of this life-threatening heart condition.

“We identified a total of 26 protein biomarkers associated with sudden cardiac arrest when cases were compared to controls, of which, 20 differentiated sudden cardiac arrest from coronary artery disease,” said Faye Norby, PhD, a research scientist at the Center for Cardiac Arrest Prevention in the Smidt Heart Institute and first author of the study. “While these biomarkers have the potential to enhance prediction of sudden cardiac arrest, future studies are needed to replicate these findings in a larger group of patients.”

Related Links:
Cedars-Sinai 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.